Evommune, Inc. 8-K

What Happened

• Evommune, Inc. announced and hosted a live webcast on April 13, 2026 highlighting the migraine treatment landscape and the role of MRGPRX2 inhibition.
• The company filed a Current Report on Form 8-K (Item 7.01, Regulation FD disclosure) to furnish the presentation as Exhibit 99.1; the report was signed by Luis Peña, President and CEO.
• The presentation will be available on Evommune’s “News & Events” page: https://ir.evommune.com/news-events/ir-calendar. The company clarifies its website content is not incorporated by reference into the 8-K and it has no obligation to update the attached presentation.

Key Details

• Date of disclosure and event: April 13, 2026.
• Filing: Current Report on Form 8-K (Regulation FD disclosure, Item 7.01); Exhibit 99.1 = Evommune presentation dated April 13, 2026.
• Signed by: Luis Peña, President and Chief Executive Officer.
• Technical exhibit note: Cover Page Interactive Data File embedded (Exhibit 104).

Why It Matters

• This disclosure informs investors about the company’s focus and public messaging on its migraine program and MRGPRX2 biology—important for assessing the company’s scientific direction and investor communications.
• Because the presentation was furnished under Regulation FD, the material was broadly released to the public; however, no financial results, revenues, or operational metrics were provided in this filing.
• Investors should watch for follow-up filings or clinical/operational updates for material developments related to the migraine program.